Apr. 21 at 11:08 AM
$DHR
🚨🚨🚨
Sales:
$5,951 million, total sales up 3.5% versus prior year; core sales growth 0.5%.
Gross profit:
$3,591 million; gross margin 60.3%, down from 61.2% due to product mix, foreign exchange and tariffs.
Operating profit:
$1,433 million; operating margin 22.6%, up 40 basis points reflecting productivity leverage and lower interest.
Net earnings:
$1,000 million, increased versus
$954 million prior year.
Net earnings per diluted common share:
$1.45, compared with
$1.32 prior year; effective tax rate 16.7%.
Revenue mix and drivers: Core sales up 0.5% year-over-year in Q1 2026; total revenue growth was aided by foreign exchange and strength in Biotechnology.
Segment performance: Biotechnology led with ~7% core growth driven by strong consumables demand; Life Sciences showed modest core gains; Diagnostics experienced headwinds.
